key: cord-0751285-of7gbv02 authors: Wang, Lan; Guo, Xiangyu; Zhao, Na; Ouyang, Yanyan; Du, Binghui; Xu, Wangli; Chan, Ta‐Chien; Jiang, Hui; Liu, Shelan title: Effects of the enhanced public health intervention during the COVID‐19 epidemic on respiratory and gastrointestinal infectious diseases in China date: 2022-02-04 journal: J Med Virol DOI: 10.1002/jmv.27619 sha: e54129f0e8b0b19a8e3f6891cd3c6744fe45cb3b doc_id: 751285 cord_uid: of7gbv02 The public health interventions to mitigate coronavirus disease 2019 (COVID‐19) could also potentially reduce the global activity of influenza. However, this strategy's impact on other common infectious diseases is unknown. We collected data of 10 respiratory infectious (RI) diseases, influenza‐like illnesses (ILIs), and seven gastrointestinal infectious (GI) diseases during 2015–2020 in China and applied two proportional tests to check the differences in the yearly incidence and mortality, and case‐fatality rates (CFRs) over the years 2015–2020. The results showed that the overall RI activity decreased by 7.47%, from 181.64 in 2015–2019 to 168.08 per 100 000 in 2020 (p < 0.001); however, the incidence of influenza was seen to have a 16.08% escalation (p < 0.001). In contrast, the average weekly ILI percentage and positive influenza virus rate decreased by 6.25% and 61.94%, respectively, in 2020 compared to the previous 5 years (all p < 0.001). The overall incidence of GI decreased by 45.28%, from 253.73 in 2015–2019 to 138.84 in 2020 per 100 000 (p < 0.001), and with the greatest decline seen in hand, foot, and mouth disease (HFMD) (64.66%; p < 0.001). The mortality and CFRs from RI increased by 128.49% and 146.95%, respectively, in 2020, compared to 2015–2019 (p < 0.001). However, the mortality rates and CFRs of seven GI decreased by 70.56% and 46.12%, respectively (p < 0.001). In conclusion, China's COVID‐19 elimination/containment strategy is very effective in reducing the incidence rates of RI and GI, and ILI activity, as well as the mortality and CFRs of GI diseases. Currently, the world is still in the middle to the high of this COVID-19 pandemic. 3 In the absence of effective pharmaceutical interventions against the SARS-CoV-2 in the early stages, most countries used non-pharmaceutical interventions (NPIs) to prevent the spread of COVID-19, including suppression/mitigation strategies. [4] [5] [6] China, especially, used an elimination/containment strategy, successfully controlling its initial COVID-19 epidemic by March 2020. 7 These NPIs and human behavioral changes used to mitigate COVID-19 could also have acted in decreasing the circulation of other respiratory diseases, such as the activity of influenza in the USA, New Zealand, and Japan. 4, [8] [9] [10] [11] [12] [13] However, the impact of NPIs on other common infectious diseases in China is not clear. 9, 11 Here, by comparing the incidence, mortality, and casefatality rates (CFRs) of respiratory and gastrointestinal infectious diseases (RI and GI diseases, respectively) in 2020 with those recorded for the previous 5 years in China, this study aimed to assess the efficacy of enhanced NPIs public health intervention during the COVID-19 epidemic on RI and GI diseases in China. This large sample size study provides the scientific evidence to guide control strategies for RI and GI diseases in China in the future. To date, a total of 40 notifiable infectious diseases are monitored by the internet-based China Information System for Disease Control and Prevention. 14 These diseases are divided into three categories-classes A (2 diseases), B (27 diseases), and C (11 diseases)-all of which must be reported within a specified timeframe, in 2 , 24 , and 24 h, respectively. 14 In this study, we collected 10 RI diseases, namely COVID-19, diphtheria, influenza, measles, scarlet fever, rubella, pertussis, meningitis, mumps, and TB (Tubercle Bacillus); seven GI diseases, namely HFMD (handfoot-and-mouth disease), dysentery, cholera, typhoid, hepatitis E, hepatitis A, and infectious diarrhea other than cholera, dysentery, typhoid and paratyphoid (hereinafter referred to as other infectious diarrheal diseases). Annual and monthly numbers of cases and deaths, the incidence and mortality data of 10 RI and seven GI diseases recorded from The criteria for confirmed, diagnosed, suspected cases of the 10 RI and 7 GI were defined according to the national diagnosis and treatment issued by the National Health Commission of the People's Republic of China. Noticeably, the diagnosis standard of confirmed influenza cases was changed since 2019, which influenza antigen rapid test is now included in the diagnosis guidelines of influenzaconfirmed cases according to the national diagnostic and treatment protocol for seasonal influenza (2019 edition). Confirmed influenza case is defined as clinical symptoms consistent with acute influenza (fever, cough, coryza, difficulty breathing) or with a history of contact with a confirmed or suspected case and a laboratory test positive for influenza virus; influenza antigen rapid test, PCR, viral isolation or a fourfold or greater increase in serum antibodies specific for this virus isolated in paired sera. According to the national influenza surveillance guideline, ILI was defined as any individual who had a body temperature of We defined incidence (per 100 000) as the number of annual incident cases divided by the population size; overall mortality (per 100 000) as the number of deaths per year divided by the total population size; and CFRs (per 1000) as the number of annual deaths divided by the number of annual incident cases. 14 Descriptive statistics were conducted using R software (R is a programming language and free software environment for statistical computing and graphics. It is designed by Ross Ihaka and Robert Gentleman, supported by the R Core Team and the R Foundation for Statistical Computing). Two proportional tests, two-ratio Z tests, and a Mann-Whitney test were applied to test the differences of NPIs' effectiveness (corresponding incidence or mortality rates or CFRs) between 2020 and the previous 5 years, between the state of emergency and nonemergency period. We also used R ggplot2 package to make the plot figures. to 168.08 per 100 000 in 2020 (p < 0.001; Figure 1A and Table S1 ). However, the overall incidence of the 10 RI in 2020 was seen to have a 37% rise, compared to the lowest annual incidence in 2015 (p < 0.001; Figure 1B ; Table S2 ). A dramatic decrease in activity was seen in seven of the RI diseases in 2020 (all p < 0.001, Table S1 ). By contrast, an increase was seen in influenza, with a 16.08% escalation in influenza (p < 0.001; Figure 1C , Table S1 ). The yearly incidence of influenza in 2020 increased by 502%, compared to the lowest incidence in 2015 (p < 0.001; Figure 1D ; Table S2 ). Differently, the incidence of TB and mumps decreased significantly in 2020 compared to the previous 5 years and the lowest level in 2019 and 2016. respectively (p < 0.001; Figure 1E -H; Tables S1 and S2). Exploring this in greater detail, it became evident that the activities of the nonvaccine preventable and nonviral RI decreased to a much greater extent than the vaccine-preventable and viral RI (all p < 0.001; Table S3 ). Table S4 ). The same results were seen in the south of China and north of China (Table S4 ). The ILI percentage in 2020 did not change when compared to the lowest level of activity in 2015 (p > 0.05, Figure 2B ). However, the influenza-positive rate decreased significantly compared to the lowest rate in 2018 (p < 0.001, Figure 2D ). Between 2015 and 2020, a total of 19 442 945 cases of the seven GI diseases investigated were reported in China. The overall incidence of the seven GI diseases decreased significantly by 45.28%, from 253.73 per 100 000 in 2015-2019 to 138.84 per 100 000 in 2020 (p < 0.001; Figure 3A ; Table S1 ). Similarly, the overall incidence of the seven GI in 2020 decreased by 40%, compared to the lowest annual incidence in 2015 (p < 0.001, Figure 3B ; Table S5 ). The incidence of all GI diseases was found to have significantly decreased, with the greatest decline seen in HFMD (64.66%; p < 0.001; Figure 3C ; Table S1 ). The yearly incidence of HFMD in 2020 has a decline of 60%, compared to the lowest incidence in 2019 (p < 0.001; Figure 3D ; Table S5 ). The incidence of other diarrhea in 2020 decreased by 10.45% than the previous 5 years while increased by 10% compared to the lowest incidence in 2015 (p < 0.001; Figure 3E ,F; Tables S1 and S5). The incidence of dysentery decreased significantly in 2020 compared to the previous 5 years and the lowest level in 2019 (p < 0.001; Figure 3G ,H; Tables S1 and S5). The incidence of each vaccine-preventable and viral GI disease in 2020 decreased by 63.87%, compared to the previous 5 years (p < 0.001, Table S3 ). The overall mortality of RI increased by 128.49% (from 0.15829 to 0.36168 per 100 000) in 2020, compared to the previous 5 years (p < 0.001; Table 1 ). The yearly mortality rates in 10 respiratory infectious diseases in 2020 increased by 177.31% compared to the lowest mortality rates in 2015 (see Table S6 ). There were a total of 5051 deaths caused by RI in 2020, of which COVID-19 accounted for 66.20% (3344/5051), see Table S7 . The CFRs from the 10 RI diseases increased by 146.95% (from 0.8714 to 2.1518 per 1000) in 2020, compared to the previous five years (p < 0.001; Table S7 ). The CFR of influenza in 2020 has an 8.5% escalation compared to the previous years (p < 0.001), see Figure 4 and Table S7 . The mortality rates of the seven GI diseases decreased by 70.56% (from 0.01094 to 0.00322 per 100 000) in 2020 compared to the previous 5 years (p < 0.001) ( Table 1 ). The overall mortality of the seven GI in 2020 increased by 11.50%, compared to the lowest annual mortality in 2017 (p = 0.28), see Table S8 . Table S7 . The CFRs of the seven GI diseases in 2020 decreased by 46.12% (from 0.0431 to 0.0232 per 1000; p < 0.001) compared to those of 2015-2019，see Figure 4 and Table S8. 3.6 | RI, ILI, and GI in emergency and routine response stage The overall incidence and mortality rates for all RI diseases increased significantly by 51.57% and 400.51% (all p < 0.001), respectively, during the period of a state of emergency (January-April 2020), as compared to the same period in the previous 5 years; however, both suddenly decreased, by 44.73% and 20.58%, with the return to nonemergency conditions in May-December 2020 (all p < 0.05; Table 2 ). The weekly percent of ILI increased by 5.71% during the state of emergency in 2020 and decreased by 9.68% during the nonemergency stage (all p < 0.05; Table 3 ). Similarly, the weekly positive influenza virus rate decreased by 28.06% and further decreased by 99.01% during the emergency and nonemergency periods in 2020 (all p < 0.001; Table 4 ). The same results were seen in the south and north of China. For the GI diseases, the incidence and mortality both decreased substantially during both the emergency and the nonemergency periods in 2020, compared to the previous five years ( Table 2 ). We found a marked decline in the overall yearly incidence rates of the ten RI, ILI activity, and the seven GI diseases, as well as GI mortality in 2020, compared to the previous 5 years in China We defined monthly incidence (per 100 000) as the number of monthly incident cases divided by the population size, and overall monthly mortality (per 100 000) as the number of deaths per month divided by the total population size. Changes = (x1−x2)/x2 × 100%; x1: average monthly incidence rate (mortality rate) in 2020; x2: average monthly incidence (mortality) rate in the previous 5 years (2015-2019) . The p value for the emergency or routine stage was computed through two proportional tests; the p value for emergency versus routine was computed through a two-ratio Z test. Abbreviations: 95% CI, 95% confidence interval; "+" = increased trend; "−" = decreased trend. The p value for the emergency or routine stage was computed through two proportional tests; the p value for emergency versus routine was computed through a two-ratio Z test. Abbreviations: 95% CI, 95% confidence interval; "+" = increased trend; "−" = decreased trend. T Abbreviations: 95% CI, 95% confidence interval; "+" = increased trend; "−" = decreased trend. WANG ET AL. which are considered to be a multiorgan disease. 29 Meanwhile, there are many technical difficulties that may arise in defining diagnoses for co-infections of influenza, all these factors contributed to the increase in fatal outcomes. 15, 17, 29 Our findings suggest that China's COVID-19 elimination/containment strategy has also been very effective in reducing the incidence rates of RI and GI diseases. However, we needed greater medical accessibility, capacity, and improvements in surveillance to decrease RI deaths during the COVID-19 epidemic. Although this study was limited in that it did not include province-specific data on RI and GI diseases, it can be of great benefit to the Chinese government as it can help them allocate resources to control common infectious diseases following the COVID-19 pandemic. As COVID-19 vaccines are implemented and NPIs strategies become relatively relaxed, the general prevalence of seasonal respiratory and gastrointestinal pathogens will return. At which time, it may be anticipated that a co-epidemic with SARS-CoV-2 will increase, which will make the situation more complicated in future seasons. 15, 30 It is very important to develop rapid dual or multiplex diagnostic tests to distinguish between these more common pathogens in the future. New surveillance technologies, pharmaceutical measures (vaccines and antivirus treatment), and NPIs must be developed to help preserve and boost the capacity and function of health systems, comprehensive strategies will be critical in controlling other classic, and emerging, infectious diseases. 3 China's COVID-19 elimination/containment strategy has been very effective in reducing the incidence rates of RI, ILI activity, and GI diseases, and mitigated the impact of the COVID-19 pandemic. However, the overall mortality rate and CFRs for the RI diseases increased significantly in 2020. Greater medical accessibility, capacity, and more rapid testing and diagnosis are needed to decrease RI deaths (especially COVID-19) during the COVID-19 epidemic in the future. Monthly incidence of overall GI; (B) the monthly incidence of overall GI in 2020 was compared to distributions in 2015-2019; (C) monthly incidence of HFMD; (D) the monthly incidence of HFMD in 2020 was compared to distributions in 2015-2019; (E) monthly incidence of other diarrhea. (F) The monthly incidence of other diarrhea in 2020 was compared to distributions in 2015-2019. (G) Monthly incidence of dysentery. (H) The monthly incidence of dysentery in 2020 was compared to distributions in WHO declares COVID-19 a pandemic Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction A tale of two cities: from influenza HxNy to SARS-CoV-z Impact of COVID-19 outbreaks and interventions on influenza in China and the United States Assessing the effect of global travel and contact restrictions on mitigating the COVID-19 pandemic Inferring the effectiveness of government interventions against COVID-19 Asymptomatic SARS-CoV-2 infections among persons entering China from Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-social distancing measures Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan Decreased influenza incidence under COVID-19 control measures COVID-19 and infant hospitalizations for seasonal respiratory virus infections, New Zealand Abrupt subsidence of seasonal influenza after COVID-19 outbreak COVID-19 versus seasonal influenza 2019-2020: USA Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study The complexity of co-infections in the era of COVID-19 Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection Reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: a retrospective study Does COVID-19 infection impact on the trend of seasonal influenza infection? 11 countries and regions, from 2014 to 2020 COVID-19 pandemic and its consequences disrupt epidemiology of enterovirus meningitis Striking decrease of enteroviral meningitis in children during the COVID-19 pandemic Active case finding with case management: the key to tackling the COVID-19 pandemic Impact of social distancing and travel restrictions on non-coronavirus disease 2019 (non-COVID-19) respiratory hospital admissions in young children in rural Alaska Covid lockdown: England sees fewer cases of colds, flu, and bronchitis Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review Physical interventions to interrupt or reduce the spread of respiratory viruses Physical interventions to interrupt or reduce the spread of respiratory viruses: summary of a Cochrane review Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China H1N1 exposure during the convalescent stage of SARS-CoV-2 infection results in enhanced lung pathologic damage in hACE2 transgenic mice COVID-19: is it just a lung disease? A case-based review Emerging pandemic diseases: how we got to COVID-19 We thank the local disease center for its epidemiological investigation report. We would also like to thank He-Hanson Xuan from The authors declare that there are no conflict of interests. This study was approved by the institutional review board of the Zhejiang Provincial Center for Disease Control and Prevention (No. 2020-026). Lan Wang, Xiangyu Guo, Hui Jiang, and Shelan Liu contributed to the study design. Xiangyu Guo contributed to data analysis. Lan Wang and Na Zhao contributed to manuscript writing. Binghui Du, Wangli Xu, and Ta-Chien Chan contributed to manuscript revision.Hui Jiang and Shelan Liu contributed to data acquisition. All authors reviewed and approved the final version. Individual patient data can be made available by the corresponding author on request. http://orcid.org/0000-0003-1369-0584